SUCAMPO PHARMACEUTICALS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2017-03-13: Study NCT03097861; Company role Collaborator; Phase Phase 3; Status Completed.
- 2011-05: Study NCT01379560; Company role Collaborator; Phase Phase 2; Status Completed.
- 2010-12: Study NCT01298219; Company role Collaborator; Phase Phase 3; Status Completed.
- 2010-04: Study NCT01096290; Company role Collaborator; Phase Phase 4; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2017-03-13 | NCT03097861 Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 3 | Completed Results posted | Chronic Idiopathic Constipation | 552 | 2017-08-17 |
| 2011-05 | NCT01379560 A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 2 | Completed | Dry Age-related Macular Degeneration | 33 | 2011-12 |
| 2010-12 | NCT01298219 Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL) | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 3 | Completed Results posted | Opioid-induced Bowel Dysfunction | 439 | 2011-11 |
| 2010-04 | NCT01096290 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications | Collaborator Lead: University of South Alabama | Phase 4 | Terminated Results posted | Constipation | 23 | 2012-09 |
| 2008-07 | NCT00737594 Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 2 | Terminated Results posted | Portal Hypertension | 9 | 2009-03 |
| 2008-04 | NCT00746395 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy | Collaborator Lead: University of South Alabama | Phase 4 | Completed Results posted | Inflammatory Bowel Disease | 45 | 2008-09 |
| 2007-08 | NCT00597428 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 3 | Completed Results posted | Opioid-Induced Bowel Dysfunction | 437 | 2009-03 |
| 2007-08 | NCT00595946 Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 3 | Completed Results posted | Opioid-Induced Bowel Dysfunction | 439 | 2009-03 |
| 2007-01 | NCT00452335 Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 4 | Completed Results posted | Constipation | 127 | 2008-10 |
| 2005-05 | NCT00399542 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation | Collaborator Lead: Sucampo Pharma Americas, LLC | Phase 3 | Completed Results posted | Irritable Bowel Syndrome; Constipation | 581 | 2006-07 |
| NCT00463723 Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty | Collaborator Lead: University Hospital Freiburg | Phase 2, Phase 3 | Terminated | Penetrating Keratoplasty |